The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein with limited expression in normal tissues but overexpressed in many kinds of tumours, including colon, gastric, pancreatic, lung, and cervical.[6][7]
In 2015, a Phase I study was completed to investigate how biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer was impacted by CS-1008. These objectives were tracked through use of trace-labeling and SPECT imaging over the course of treatment and found heterogeneity of tigatuzumab uptake in tumors, that tigatuzumab uptake is not dose dependent, and that tigatuzumab uptake is predictive of clinical response in the treatment of metastatic colorectal cancer.[7]
Referencesedit
^"International Nonproprietary Names for Pharmaceutical Substances (INN): List 60" (PDF). WHO Drug Information.
^. NCI Cancer Bulletin. 6 (8). 21 April 2009. Archived from the original on 28 July 2011.
^Clinical trial number NCT00969033 for "CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin" at ClinicalTrials.gov
^Clinical trial number NCT00991796 for "CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)" at ClinicalTrials.gov
^Clinical trial number NCT00945191 for "Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer" at ClinicalTrials.gov
^"Drug Dictionary: CS-1008". National Cancer Institute.
^ abCiprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, et al. (August 2015). "Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer". Journal of Clinical Oncology. 33 (24): 2609–16. doi:10.1200/JCO.2014.60.4256. PMC4881374. PMID 26124477.
tigatuzumab, 1008, monoclonal, antibody, treatment, cancer, october, 2009, update, clinical, trial, treatment, pancreatic, cancer, phase, trials, colorectal, cancer, small, cell, lung, cancer, ovarian, cancer, have, been, completed, monoclonal, antibodytypewho. Tigatuzumab CS 1008 is a monoclonal antibody 1 for the treatment of cancer As of October 2009 update a clinical trial for the treatment of pancreatic cancer 2 Phase II trials for colorectal cancer 3 non small cell lung cancer 4 and ovarian cancer 5 have been completed TigatuzumabMonoclonal antibodyTypeWhole antibodySourceHumanized from mouse TargetTNFRSF10B TRAIL R2 Clinical dataATC codenoneIdentifiersCAS Number918127 53 4 NChemSpidernoneUNII237GB6IDKOChemical and physical dataFormulaC 6406H 9924N 1716O 2012S 46Molar mass144646 62 g mol 1 N Y what is this verify The drug targets member 10b of the tumor necrosis factor receptor superfamily TNFRSF10B better known as death receptor 5 or trail receptor 2 a protein with limited expression in normal tissues but overexpressed in many kinds of tumours including colon gastric pancreatic lung and cervical 6 7 In 2015 a Phase I study was completed to investigate how biodistribution quantitative tumor uptake and antitumor response in patients with metastatic colorectal cancer was impacted by CS 1008 These objectives were tracked through use of trace labeling and SPECT imaging over the course of treatment and found heterogeneity of tigatuzumab uptake in tumors that tigatuzumab uptake is not dose dependent and that tigatuzumab uptake is predictive of clinical response in the treatment of metastatic colorectal cancer 7 References edit International Nonproprietary Names for Pharmaceutical Substances INN List 60 PDF WHO Drug Information Combination Therapy Targets Pancreatic Cancer Stem Cells NCI Cancer Bulletin 6 8 21 April 2009 Archived from the original on 28 July 2011 Clinical trial number NCT00969033 for CS 1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First line Treatment With Oxaliplatin at ClinicalTrials gov Clinical trial number NCT00991796 for CS 1008 With Carboplatin Paclitaxel in Chemotherapy naive Subjects With Metastatic or Unresectable Non small Cell Lung Cancer NSCLC at ClinicalTrials gov Clinical trial number NCT00945191 for Combination Chemotherapy With CS 1008 to Treat Ovarian Cancer at ClinicalTrials gov Drug Dictionary CS 1008 National Cancer Institute a b Ciprotti M Tebbutt NC Lee FT Lee ST Gan HK McKee DC et al August 2015 Phase I Imaging and Pharmacodynamic Trial of CS 1008 in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology 33 24 2609 16 doi 10 1200 JCO 2014 60 4256 PMC 4881374 PMID 26124477 nbsp This monoclonal antibody related article is a stub You can help Wikipedia by expanding it vte nbsp This antineoplastic or immunomodulatory drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Tigatuzumab amp oldid 1160194760, wikipedia, wiki, book, books, library,
